Which of the following is NOT a potential complication of total parenteral nutrition (TPN)?

Which of the following is NOT a potential complication of total parenteral nutrition (TPN)?

• A. Ketoacidosis
• B. Hyperglycemia
• C. Hypoglycemia
• D. Hypophosphatemia

Answer: (A)

Total parenteral nutrition delivers a continuous glucose-rich solution, amino acids, and fats directly into the bloodstream, so the metabolic issues to watch for are driven by glucose load and shifts of electrolytes driven by insulin. Hyperglycemia is a common problem because the high dextrose infusion can raise blood glucose, especially in patients with diabetes or stress. Hypoglycemia can occur if the PN is interrupted or mismanaged and glucose delivery drops suddenly before other glucose sources or insulin adjust accordingly. Hypophosphatemia arises when a large carbohydrate load drives insulin-driven uptake of phosphate into cells, which lowers serum phosphate and can cause muscle and cardiac problems if severe. These are well-recognized risks of PN therapy and require careful glucose and electrolyte monitoring and timely supplementation or insulin management. Ketoacidosis, on the other hand, is not a typical consequence of PN. The carbohydrate in the PN tends to stimulate insulin release and suppress ketone production; ketoacidosis usually stems from significant insulin deficiency or unrecognized diabetes with inadequate exogenous insulin. In the context of PN, if glucose and insulin management are appropriate, ketosis is not a common issue. So the option that does not fit as a typical PN complication is ketoacidosis, whereas hyperglycemia, hypoglycemia, and hypophosphatemia are established metabolic risks to monitor during PN therapy.

Total parenteral nutrition delivers a continuous glucose-rich solution, amino acids, and fats directly into the bloodstream, so the metabolic issues to watch for are driven by glucose load and shifts of electrolytes driven by insulin.

Hyperglycemia is a common problem because the high dextrose infusion can raise blood glucose, especially in patients with diabetes or stress. Hypoglycemia can occur if the PN is interrupted or mismanaged and glucose delivery drops suddenly before other glucose sources or insulin adjust accordingly. Hypophosphatemia arises when a large carbohydrate load drives insulin-driven uptake of phosphate into cells, which lowers serum phosphate and can cause muscle and cardiac problems if severe. These are well-recognized risks of PN therapy and require careful glucose and electrolyte monitoring and timely supplementation or insulin management.

Ketoacidosis, on the other hand, is not a typical consequence of PN. The carbohydrate in the PN tends to stimulate insulin release and suppress ketone production; ketoacidosis usually stems from significant insulin deficiency or unrecognized diabetes with inadequate exogenous insulin. In the context of PN, if glucose and insulin management are appropriate, ketosis is not a common issue.

So the option that does not fit as a typical PN complication is ketoacidosis, whereas hyperglycemia, hypoglycemia, and hypophosphatemia are established metabolic risks to monitor during PN therapy.